Gemoscan Canada, Inc.

Gemoscan Canada, Inc.

March 05, 2012 10:49 ET

Gemoscan Canada Announces Appointment of Vice President, Investor Relations

TORONTO, ONTARIO--(Marketwire - March 5, 2012) - Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") - (TSX VENTURE:GES) (MUN:1GE) is pleased to announce the appointment of Ann Hawley as Vice President, Investor Relations, effective immediately. Ms. Hawley will report to President and CEO, Brian Kalish.

Ms. Hawley brings more than 20 years of experience in the investor relations field, across multiple markets and industries, to the Gemoscan team. Prior to joining Gemoscan, she was Vice President Investor Relations at Colossus Minerals Inc., an emerging gold producer. Previously she was Director Investor Relations and Corporate Communications at Ivernia Inc., a base metals mining, exploration and development company. Prior to Ivernia, she was Director, Investor Relations at Intrepid Mines Limited, and held senior investor relations positions in several technology and network communications companies based in Silicon Valley, California. Ms. Hawley will be the primary interface between Gemoscan and the investment community and she will oversee the development and implementation of an overall corporate communications plan focused on building relationships with the broker and institutional investment communities while also driving general market awareness and communications strategies at Gemoscan.

As part of the compensation package, which includes an annualized salary, Gemoscan will issue Ms. Hawley 300,000 incentive stock options to be granted pursuant to the Company's stock option plan (the "Option Plan") and the rules of the TSX Venture Exchange. The options are exercisable at $0.37 for five years in accordance with the Option Plan and will vest in four equal installments every three months commencing on the grant date.


Founded in 2003, Gemoscan Canada Inc. owns and markets the HEMOCODE™ Food Intolerance System, a personalized naturopathic nutritional program that promotes well-being. HEMOCODE™ uses patented technology and services to provide consultation and recommendations to simplify the management of food sensitivities. Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange (TSX-V) under the symbol GES.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information